Healthcare Industry News: Sanofi
News Release - December 22, 2008
Biovail Enters into Commercial Alliance for AplenzinAgreement Reached with Sanofi-aventis US
Biovails Supply Price Ranges from 25% to 35% of Net Sales
Product Launch Anticipated in Q1/2009
TORONTO--(HSMN NewsFeed)--Biovail Corporation (NYSE:BVF )(TSX:BVF ) today announced that a subsidiary, Biovail Laboratories International SRL (BLS), has entered into a supply agreement with Sanofi-aventis US for the marketing and distribution of Aplenzin(TM) (bupropion hydrobromide tablets) in the United States and Puerto Rico.
“We are pleased to have entered into this partnership with Sanofi aventis US,” said Bill Wells, Biovail’s Chief Executive Officer and President of BLS. “The support of their world-class marketing organization bodes well for a successful launch for Aplenzin(TM).”
Aplenzin(TM), which was approved by the United States Food and Drug Administration (FDA) in April 2008, is indicated for the treatment of major depressive disorder. Biovail anticipates that Sanofi aventis US will launch the 348mg and 522mg dosage strengths of Aplenzin(TM) in the first quarter of 2009.
Under the terms of the agreement, Biovail will manufacture, supply and sell Aplenzin(TM) to Sanofi aventis US at contractually determined prices, which will be based on Sanofi aventis US’ net selling price. Biovail’s supply price will range from 25% to 35% of net sales, depending on the level of net sales of Aplenzin(TM). Other financial terms were not disclosed.
Caution Regarding Forward-Looking Information and "Safe Harbor" Statement
To the extent any statements made in this release contain information that is not historical, these statements are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and may be forward-looking information under applicable Canadian provincial securities legislation (collectively, “forward-looking statements”). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, statements concerning the anticipated commercialization and launch of Aplenzin(TM) and the potential success of the launch of Aplenzin(TM), and can generally be identified by the use of words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “may” and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.
Although Biovail believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making forward-looking statements, including, but not limited to, factors and assumptions regarding prescription trends, pricing and the formulary and/or Medicare/Medicaid positioning for our products, the competitive landscape in the markets in which we compete, including, but not limited to, the availability or introduction of generic formulations of our products, timelines associated with the development of, and receipt of regulatory approval for, our new products, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: the difficulty of predicting FDA and Canadian Therapeutic Products Directorate approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, uncertainties associated with the development, acquisition and launch of new products, reliance on key strategic alliances, contractual disagreements with third parties, availability of raw materials and finished products, the regulatory environment, the expense, timing and uncertain outcome of legal and regulatory proceedings and settlements thereto, market liquidity for our common shares and our satisfaction of applicable laws for the repurchase of our common shares, availability of capital, satisfaction of applicable laws for dividend payments and the ability to generate operating cash flow, the continuation of the recent financial market turmoil, consolidated tax rate assumptions, fluctuations in operating results and other risks detailed from time to time in Biovail’s filings with the Securities and Exchange Commission and the Canadian Securities Administrators, as well as Biovail’s ability to anticipate and manage the risks associated with the foregoing. Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this news release, as well as under the heading “Risk Factors” contained in Item 3(D) of Biovail’s most recent Annual Report on Form 20-F and contained in Biovail’s Form 6-K for the quarterly period ended September 30, 2008.
The Company cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Biovail’s forward-looking statements to make decisions with respect to the Company, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Biovail undertakes no obligation to update or revise any forward-looking statement.
About Biovail Corporation
Biovail Corporation is a specialty pharmaceutical company engaged in the formulation, clinical testing, registration, manufacture, and commercialization of pharmaceutical products. The Company is focused on the development and commercialization of medicines that address unmet medical needs in niche specialty central nervous system (CNS) markets. For more information about Biovail, visit the Company’s Web site at www.biovail.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.